Giant cell tumors of the sacrum-a nationwide study on midterm results in 26 patients after intralesional excision

L. van der Heijden, M. van der Sande, I. van der Geest, H. Schreuder, B. van Royen, P. Jutte, J. Bramer, F. Oner, A. van Noort-Suijdendorp, H. Kroon, P. Dijkstra

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Scopus)


Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT). We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U. Recurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024). Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function
Original languageEnglish
Pages (from-to)1949-1962
JournalEuropean Spine Journal
Issue number9
Publication statusPublished - 2014

Cite this